Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Appoints Six Scientists to Board

Premium

CAMBRIDGE, Mass.--Millennium Pharmaceuticals here has appointed six scientists to its scientific advisory board, including Chairman Christopher Walsh, Frank Austen, Gerald Fink, Raju Kucherlapati, Eric Lander, and Harvey Lodish. Mark Levin, Millennium's CEO, commented, "The expertise of these six scientific leaders will further drive Millennium's high-throughput drug discovery platform towards our goal of creating therapeutic products." Millennium is a drug discovery company that makes widespread use of bioinformatics.

Walsh is the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology, and Austen is the Theodore Beveire Bayles Professor of Medicine, at the Harvard Medical School. Fink is director and a founding member of the Whitehead Institute for Biomedical Research. Kucherlapati, a founder of Millennium, is a director of the company and chairman of molecular genetics at the Albert Einstein College of Medi cine. Lander is a member of the White head Institute and director of the MIT Genome Center, and Lodish is a professor of biology at MIT and a founding member of the Whitehead Institute.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.